Imatinib use in the management of a patient with Doege-Potter syndrome.

Summary: Doege-Potter syndromeis a paraneoplastic syndrome characterized by nonislet cell tumor hypoglycemia due to a solitary fibrous tumor, which produces insulin-like growth factor II. In this report, we present the case of a 67-year-old male with recurrent and refractory hypoglycemia due to DPS successfully treated with imatinib. He initially presented with neuroglycopenic symptoms and dyspnea secondary to a giant tumor in the left hemithorax, which was totally resected. During follow-up, 7 years later, he presented with thoracoabdominal tumor recurrence associated with severe hypoglycemia and underwent subtotal tumor resection, with a subsequent improvement of symptoms. The following year, he had a recurrence of his intra-abdominal tumor, which was unresectable, associated with severe hypoglycemia refractory to dextrose infusion and corticosteroids, thus receiving imatinib with a favorable response. The clinical presentation, diagnostic approach, progression of the disease, and response to treatment with imatinib in the management of a patient with large, recurrent, and unresectable mesenchymal tumors with insulin-like growth factor-2 secretion causing hypoglycemiahighlight the importance of this case report. Learning points: Doege-Potter syndrome (DPS) is a rare cause of tumoral hypoglycemia of non-pancreatic origin. Some malignant or benignant neoplasms have ectopic secretion of insulin-like growth factor-2. Total surgical removal is the principal treatment in patients with DPS. Tyrosine kinase inhibitors management in DPS may contribute to improved tumor control in patients with unresectable tumors and severe hypoglycemia.

Control metabólico y su relación con enfermedad arterial periférica en sujetos con diabetes mellitus tipo 2: Estudio caso-control pareado

Objetivo : Evaluar la relación entre control metabólico y enfermedad arterial periférica (EAP) en pacientes con diabetes mellitus tipo 2 (DM2) del hospital María Auxiliadora (HMA). Material y métodos : Estudio caso-control pareado para sexo, de un análisis secundario basado en datos del servicio de endocrinología del HMA, Lima-Perú. Los casos con EAP, fueron aquellos con índice tobillo-brazo (ITB) < 0,9. Los controles fueron aquellos con ITB entre 0,9 y 1,3 en una relación 4:1 con respecto a los casos. Se definió como mal control metabólico si presentaron al menos uno de las siguientes: hemoglobina glicosilada ≥ 7 %, presión arterial sistólica ≥ 140 mm Hg, presión arterial diastólica ≥ 90 mm Hg, colesterol HDL< 40 mg/dl (varón) o < 50 mg/dl (mujer), colesterol LDL ≥ 100 mg/dl y triglicéridos ≥ 150 mg/dl. Se calculó el Odds ratio (OR) de mal control metabólico, tanto crudo como ajustado, según presencia de EAP mediante regresión logística. Resultados : Incluimos a 39 casos y 157 controles. Un 94,9 % y 82,2 % de los casos y controles presentaron mal control metabólico respectivamente (p<0,05). Al ajustar a edad, tiempo de diabetes, índice de masa corporal y antecedente de tabaco, los pacientes con mal control metabólico presentaron un OR de 5,45; (IC 95 % 1,17 - 25,2); p=0,030 de presentar enfermedad arterial periférica definido por ITB<0,9. Conclusión : El mal control metabólico presenta una relación independiente con EAP en pacientes con DM2 del Hospital María Auxiliadora. Metas terapéuticas centradas solo en la glicemia, elevarían la carga de enfermedad de complicaciones macrovasculares.

Objective : To assess the relationship between metabolic control and peripheral arterial disease (PAD) in patients with type 2 diabetes mellitus (DM2) in Maria Auxiliadora Hospital (MAH). Material and methods : This is a sex-matched case control study with a secondary analysis based on data from the endocrinology service of MAH, Lima, Peru. Cases with PAD were defined as those with 50 mg/dL (females), LDL cholesterol ≥100 mg/dL and triglycerides ≥150 mg/dL. Odds ratio values for poor metabolic control were calculated, both crude and adjusted, according to the presence or PAD, by using logistic regression. Results : We included 39 cases and 157 controls. A great majority of cases (94.9%) and of controls (82.2%) had poor metabolic control, respectively (p<0.05). When adjusting for age, time with diabetes, body mass index, and history of tobacco use, patients with poor metabolic control had OR at 5.45 (95% CI: 1.17 - 25.2) and p= 0.030 for having peripheral arterial disease, as defined by ATAI <0.9. Conclusion : Poor metabolic control showed and independent relationship with PAD in DM2 patients in Maria Auxiliadora Hospital. If therapy was only centered in glycemic control, it would increase the burden of disease of macrovascular complications.

Glucemia de ingreso asociada a mortalidad y estancia hospitalaria en un servicio multidisciplinario de un hospital nacional peruano

Objetivo: Evaluar la asociación entre glucemia de ingreso y desenlaces adversos en pacientes hospitalizados con COVID-19 en un hospital nacional peruano. Métodos: Estudio observacional tipo cohorte retrospectiva. Se revisaron historias clínicas electrónicas de pacientes hospitalizados por COVID-19 en un servicio de especialidades. Los pacientes se clasificaron según niveles de glucemia al ingreso: ≤ y >140mg/dL; el desenlace primario fue mortalidad y el secundario un compuesto que incluyó mortalidad, shock séptico, ventilación mecánica o traslado a UCI. Se evaluó la estancia hospitalaria y se realizó un subanálisis de regresión logística multivariada en pacientes diabéticos. Resultados: Se evaluaron 169 pacientes, media de edad 61 años, 64.5% varones. 71% presentaban alguna comorbilidad, siendo las más frecuentes: hipertensión arterial (34%), obesidad (30%), diabetes (26%). El 70% presentó gravedad tomográfica. La mediana de glucemia de ingreso fue 126.5mg/dL (RIC: 109-157mg/dL), uno de cada 3 presentó glucemia >140mg/dL. La tasa de mortalidad fue 9700 muertes por cada 100 000 personas-semana, con frecuencia de 21.3%. No se encontró diferencia significativa entre hiperglucemia y normoglucemia, tanto en mortalidad como desenlace compuesto. Los pacientes con hiperglucemia de ingreso presentaron mayor estancia hospitalaria que los normoglucémicos (19 días vs 13 días, p180mg/dL presentó OR de 6.42 (IC95%: 1.07-38.6), ajustado a edad y a gravedad clínica de ingreso. Conclusiones: La hiperglucemia al ingreso se asoció a mayor estancia hospitalaria, y los pacientes diabéticos con hiperglucemia >180mg/dL presentaron un riesgo 6 veces mayor de presentar desenlace adverso.

Objective: Evaluate the association between glycemia on admission and adverse outcomes in hospitalized patients with COVID19 in a Peruvian national hospital. Methods: Retrospective, observational cohort study. We collected data from electronic medical records of COVID19 patients in a medical specialties service. Patients were classified according to blood glucose levels on admission: ≤ and >140mg/dL. Primary outcome was mortality, and the secondary a composite that included mortality, septic shock, mechanical ventilation, or transfer to ICU. We also evaluated hospital stay and a multivariate logistic regression sub analysis was performed in diabetic patients. Results: 169 patients were evaluated. The mean age was 61 years, 64.5% were male. 71% had at least one comorbidity, the most frequent: arterial hypertension (34%), obesity (30%) and diabetes (26%). 70% presented tomographic gravity. Median blood glucose at admission was 126.5mg/dL (IQR: 109-157mg/dL), one of every 3 had blood glucose levels >140mg/dL. Mortality rate was 9700 deaths per 100000 person-weeks, with a frequency of 21.3%. No significant difference was found between hyperglycemia and normoglycemia, mortality and in composite outcome. Patients with hyperglycemia on admission had longer hospital stay than normoglycemic patients (19 vs 13 days, p180mg/dL presented OR of 6.42 (95% CI: 1.07-38.6) for composite outcome, adjusted for age and clinical severity at admission. Conclusions: Hyperglycemia at admission was associated with a longer hospital stay and diabetic patients with hyperglycemia >180mg/dL had a 6-fold increased risk of presenting an adverse outcome.

[Clinical-epidemiological profile of patients with thyrotoxic periodic paralysis in two peruvian hospitals]. / Perfil clínico-epidemiológico de pacientes con parálisis periódica tirotóxica en dos hospitales peruanos.

Background: Thyrotoxic Periodic Paralysis (PPT) is an uncommon complication of hyperthyroidism, it is the most frequent cause of acute flaccid paralysis in adults. Material and methods: A retrospective observational study was carried out in 2 reference hospitals of the social security in Lima-Peru, which included 22 patients diagnosed with PPT during the period 2014-2021. Results: the average age at diagnosis was 35.77 ± 9.6 years, all of mixed race, in 82% of the patients the diagnosis of hyperthyroidism was established from this entity, the etiology in 95% was autoimmune (Graves-Basedow) except for one whose etiology was toxic multinodular goiter. The triggering event reported in 54% of patients was the intake of copious food high in carbohydrates, followed by exercise (27%), the most frequent presentation time was during the morning (41% of the cases), the main weakness pattern compromised lower limbs (45% paraplegia, 18% paraparesis), only 36% were diagnosed with PPT in their first episode of motor weakness. Conclusions: We consider that this condition should be suspected in any young male patient of any ethnicity with acute muscle weakness, associated with low serum potassium levels and symptoms of thyrotoxicosis, although its absence should not rule out the diagnosis. The precipitating factor should be identified as much as possible and initial therapy with propanolol with or without intravenous or oral potassium replacement should be established, with adequate subsequent monitoring to minimize the risk of rebound hyperkalemia.

Introducción: la paralisis periodica tirotóxica (PPT) es una complicación poco común del hipertiroidismo, corresponde la causa más frecuente de parálisis aguda flácida del adulto. Material y métodos: se realizó un estudio observacional retrospectivo en 2 hospitales referenciales del seguro social en Lima-Perú, que incluyo a 22 pacientes (21 hombres, 1 mujer) diagnosticados con PPT durante el periodo 2014-2021. Resultados: la edad promedio al diagnóstico fue de 35.77 ± 9.6 años, todos de raza mestiza, en 82% de los pacientes el diagnostico de hipertiroidismo fue establecido a partir de esta entidad, la etiología en el 95% fue autoinmune (enfermedad de Graves-Basedow) excepto uno cuya etiología fue bocio multinodular tóxico. El evento desencadenante reportado en 54% de pacientes fue la ingesta de comida copiosa alta en carbohidratos, seguido del ejercicio (27%), el horario más frecuente de presentación fue durante la mañana ( 41% de los casos), el patrón de debilidad principal comprometió miembros inferiores(45% paraplejia, 18% paraparesia), solo 36% fue diagnosticado de PPT en su primer episodio de debilidad motora. Conclusiones: consideramos que se debe sospechar esta condición en cualquier paciente varón joven de cualquier etnia con debilidad muscular aguda, asociado a niveles séricos bajos de potasio y síntomas de tirotoxicosis, aunque su ausencia no debe descartar el diagnostico. Se debe identificar en lo posible el factor precipitante e instaurar terapia inicial con propanolol con o sin reemplazo de potasio endovenoso u oral, con monitoreo posterior adecuado que minimice el riesgo de hiperpotasemia de rebote.

Nationwide prevalence and clinical characteristics of inpatient diabetic foot complications: A Peruvian multicenter study.

OBJECTIVE: To evaluate the burden of diabetic foot complications amongst inpatients in Peru. MATERIALS AND METHODS: Cross-sectional multicenter study, performed in public hospitals, in one-day enrollment between October and December 2018. RESULTS: We included 8346 patients from 39 national hospitals. Diabetic foot (DF) inpatient point prevalence was 2.8% (CI 95% 2.4-3.1), and DF point prevalence among Diabetes Mellitus (DM) inpatients was 18.9% (CI 95% 16.7-21.1). DF prevalence was higher in jungle and coastal hospitals than highlands ones, and there was no difference according to its care complexity level. Of the 234 patients with DF, 73% were males, age average was 62 ± 12 years, with DM mean time duration of 15 ± 9.9 years. Regarding to DF etiology, 91% and 68% had some degree of peripheral neuropathy and peripheral artery disease, respectively. According to the Infectious Diseases Society of America criteria, 61% presented moderate to severe infections, and 40% had bone involvement. Debridement within 48 h was performed in 36% of sepsis cases. CONCLUSION: Peru has a substantial burden of DF disease, with a greater share of that burden falling on less equipped hospitals in the country's jungle and coastal regions. Interdisciplinary teams and pathways may improve the time of surgical debridement in the highest risk patients.

Validación de la estratificación dinámica modificada de riesgo de recidiva de carcinoma diferenciado de tiroides, en pacientes atendidos en el periodo 2004-2005 en el Hospital Nacional Edgardo Rebagliati Martins / Validation of the modified dynamic stratification of risk of recurrence of differentiated thyroid carcinoma in patients attended in the period 2004-2005 at the National Hospital Edgardo Rebagliati Martins

Introducción: Existen diversas estratificaciones para predecir el riesgo de recurrencia del carcinoma diferenciado de tiroides (CDT), sin embargo ninguna de éstas tanto las estáticas como las dinámicas han sido validadas para nuestra población. Objetivo: Validar la estratificación dinámica modificada de riesgo de recidiva de CDT, en pacientes atendidos en el periodo 2004-2005 en el Hospital Nacional Edgardo Rebagliati Martins, Lima-Perú. Método: Tipo de estudio: Cohorte retrospectiva y observacional. Sujetos: 145 pacientes con diagnóstico de CDT, atendidos en el Servicio de Endocrinología del Hospital Nacional Edgardo Rebagliati Martins desde enero 2004 hasta diciembre 2005, quienes han recibido tratamiento inicial convencional con tiroidectomía total y ablación con I131. Se realizan las estratificaciones estáticas de la ATA y del SLAT, y las dinámicas: Demorada (EDR) y Modificada (EDRM) al 1-2 años post-ablación; luego se realizaron exámenes de seguimiento y se determinó la respuesta al tratamiento cada 2 años hasta el último control registrado en la historia clínica. Resultados: el promedio de tiempo de seguimiento de los 145 pacientes fue de 8.4 años, siendo el 93 por ciento mujeres con edad promedio de 48.3 años. En la EDR, el riesgo relativo (IC 95 por ciento) de recurrencia/persistencia fue de 7.06 (2.41-20.66) en el grupo de respuesta aceptable, y 10.1 (3.72-27.36) en el grupo de respuesta incompleta, comparados con el grupo de respuesta excelente (p=0.000). En la EDRM, el riesgo relativo (IC 95 por ciento) de recurrencia/persistencia fue de 3.83 (0.84-17.29) en el grupo de respuesta aceptable, y 9.1 (2.39-34.27) en el grupo de respuesta incompleta, comparados con el grupo de respuesta excelente (p=0.001). Siendo la sensibilidad y especificidad de EDR de 87.1 por ciento y 66.1 por ciento respectivamente, con área bajo la curva de 0.77; y en EDRM, se encontró una sensibilidad y especificidad de 100 por ciento y 46.5 por ciento respectivamente, con área...

Introduction: There are several stratifications to predict the risk of recurrence of differentiated thyroid carcinoma (DTC), however none of these both static and dynamic have been validated for our population. Objective: To validate the Modified dynamic risk stratification for predicting recurrence of CDT in patients treated in 2004-2005 at the National Hospital Edgardo Rebagliati Martins, Lima-Peru. Method: Type of study: Retrospective observational cohort. Subjects: 145 patients diagnosed with CDT, treated at the Department of Endocrinology, National Hospital Edgardo Rebagliati Martins from January 2004 to December 2005, who received conventional initial treatment with total thyroidectomy and 1311 ablation. Static stratifications of the ATA and the SLAT are made, and dynamics: Delayed (EDR) and property (EDRM) at 1-2 years post-ablation; then follow-up examinations were performed and response to treatment every two years to the last visit recorded in the medical record was determined. Results: The average follow-up of 145 patients was 8.4 years, with 93 per cent women with a mean age of 48.3 years. In the EDR, the relative risk (95 per cent) of recurrence / persistence was 7.06 (2.41-20.66) in the group of acceptable response to therapy, and 10.1 (3.72-27.36) in the group of incomplete response, compared with the group of excellent response (p=0.000). In the EDRM, the relative risk (95 per cent) of recurrence / persistence was 3.83 (0.84-17.29) in the group of acceptable response to therapy, and 9.1 (2.39-34.27) in the group of incomplete response, compared with the group of excellent response (p=0.001). The sensitivity and specificity of EDR were 87.1 per cent and 66.1 per cent respectively, and an area under the curve of 0.77; and the sensitivity and specificity of EDRM were 100 per cent and 46.5 per cent respectively, and area under the curve of 0.78. Conclusion: Both dynamic risk stratifications of recurrence (EDR and EDRM) in CDT, adequately predict...